Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joy M Greer

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Neuron|January 10, 2002
Hoxb8 is required for normal grooming behavior in miceJoy M Greer, Mario R Capecchi
Neuron|May 6, 2006
Pten and the brain: sizing up social interactionJoy M Greer, Anthony Wynshaw-Boris
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical EfficacyJennifer R Diamond, Valentina Boni, Emerson Lim, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trialDésirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trialPhilip Mease, Laura C Coates, Philip S Helliwell, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Neuron|January 10, 2002
Hoxb8 is required for normal grooming behavior in miceJoy M Greer, Mario R Capecchi
Neuron|May 6, 2006
Pten and the brain: sizing up social interactionJoy M Greer, Anthony Wynshaw-Boris
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical EfficacyJennifer R Diamond, Valentina Boni, Emerson Lim, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trialDésirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, et al.
Lancet (London, England)|October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trialPhilip Mease, Laura C Coates, Philip S Helliwell, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Pageof 1